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Abstract
The mental retardation, autistic features, and behavioral abnormalities characteristic of the Fragile X mental retardation
syndrome result from the loss of function of the RNA–binding protein FMRP. The disease is usually caused by a triplet repeat
expansion in the 59UTR of the FMR1 gene. This leads to loss of function through transcriptional gene silencing, pointing to a
key function for FMRP, but precluding genetic identification of critical activities within the protein. Moreover, antisense
transcripts (FMR4, ASFMR1) in the same locus have been reported to be silenced by the repeat expansion. Missense
mutations offer one means of confirming a central role for FMRP in the disease, but to date, only a single such patient has
been described. This patient harbors an isoleucine to asparagine mutation (I304N) in the second FMRP KH-type RNA–
binding domain, however, this single case report was complicated because the patient harbored a superimposed familial
liver disease. To address these issues, we have generated a new Fragile X Syndrome mouse model in which the endogenous
Fmr1 gene harbors the I304N mutation. These mice phenocopy the symptoms of Fragile X Syndrome in the existing Fmr1–
null mouse, as assessed by testicular size, behavioral phenotyping, and electrophysiological assays of synaptic plasticity.
I304N FMRP retains some functions, but has specifically lost RNA binding and polyribosome association; moreover, levels of
the mutant protein are markedly reduced in the brain specifically at a time when synapses are forming postnatally. These
data suggest that loss of FMRP function, particularly in KH2-mediated RNA binding and in synaptic plasticity, play critical
roles in pathogenesis of the Fragile X Syndrome and establish a new model for studying the disorder.
Citation: Zang JB, Nosyreva ED, Spencer CM, Volk LJ, Musunuru K, et al. (2009) A Mouse Model of the Human Fragile X Syndrome I304N Mutation. PLoS
Genet 5(12): e1000758. doi:10.1371/journal.pgen.1000758
Editor: Gregory A. Cox, The Jackson Laboratory, United States of America
Received October 17, 2008; Accepted November 9, 2009; Published December 11, 2009
Copyright:  2009 Zang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (R01 NS34389 (RBD), R01 NS40955 (RBD), R01 HD040647 (JCD), R01 NS045711 (KMH), R01
HD052731 (KMH)), Autism Speaks (KMH), the NICHD/NIH Fragile X Center at Baylor College of Medicine (RP), and NIH MSTP-GM07739 to JBZ. RBD is a Howard
Hughes Medical Institute Investigator. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: darneje@rockefeller.edu
Introduction
Missense mutations have been especially informative for
establishing links between genetics and protein function in human
disease. For example, missense mutations have advanced our
understanding of the relationship between autism and mutations
in genes including neuroligin-3 [1,2], neurexin-1 [3], shank 3 [4],
and MeCP2 [5]. Such mutations have not generally been of help
in understanding the devastating effects of the loss of function of
the Fragile X mental retardation protein (FMRP), which include
complex behavioral deficits including mental retardation, autism,
and seizures [6]. In nearly all cases, the Fragile X Syndrome is
caused by transcriptional silencing of the fragile X mental
retardation 1 (FMR1) gene as a result of CGG repeat expansion
and hypermethylation of CpG islands in the 59UTR region
(reviewed in [7]), culminating in loss of FMRP expression.
Moreover, antisense transcripts (FMR4, AS-FMR1) in the same
locus have been reported to be silenced by the repeat expansion,
raising the possibility that their loss of function may contribute to
the syndrome [8,9]. While this transcriptional silencing precludes
structure-function analysis of FMRP, a single severely affected
Fragile X Syndrome patient with a de novo missense mutation in
FMRP has the potential to address this issue. This patient has
marked macroorchidism, with testicular volume exceeding 100ml,
and mental retardation, with IQ measured below 20, and harbors
a mutation in a conserved isoleucine changing it to an asparagine
(I304N) [10]. Nonetheless, uncertainty has surrounded the
significance of this clinical observation, in part because only a
single such patient has been described, and in part because this
patient has a confounding liver disease [10].
Previous efforts at modeling defects in FMRP have centered on
generation of an Fmr1 null mouse (Fmr1
tm1Cgr). This mouse has
defects in synaptic plasticity [11–18] and long, thin dendritic
spines [19,20] similar to those found in human brain [21,22].
Understanding the biochemical mechanism by which FMRP
mediates proper synaptic plasticity and/or maturation is an area of
intense interest.
Studies of FMRP have been necessarily restricted to in vitro and
cell culture models, since the mouse model is a null. FMRP
associates with polyribosomes in tissue culture cells [23–25] and
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FXR1P, associate with components of the RNA-induced silencing
complex (RISC) in Drosophila and mammalian cells [29–32], and
FXR1P is required to mediate miRNA-dependent translational
activation in tissue culture cells [33,34]. FMRP has also been
proposed to have a role in mRNA transport, trafficking mRNA
targets as granules from cytoplasm to synapses in a microtubule-
dependent manner in primary neurons [35–37]. FMRP has also
been suggested to regulate PSD-95 mRNA stability [38]. A
common theme associated with these diverse cellular roles is that a
critical function of FMRP is binding to specific RNA targets.
FMRP has functional domains involved in RNA binding,
protein:protein interactions and nuclear-cytoplasmic shuttling.
FMRP RNA binding domains include two tandem KH-type
domains (hnRNPK homology), an arginine and glycine-rich RNA
binding domain (RGG box) [39,40], and an N-terminal domain
similar to Tudor/Agenet domains that may be involved in both
RNA binding and protein-protein interactions [41–44]. Protein
interaction domains include an N-terminal region responsible for
homodimerization and heterodimerization with its autosomal
homologs FXR1P and FXR2P [45,46]. Finally, FMRP has a
nuclear localization signal (NLS) mapped to approximately 100
nucleotides of the N-terminus [47], and a Rev-like nuclear export
signal (NES) C-terminal to the KH domains, which, when
mutated at critical leucines, causes accumulation of FMRP in
the nucleus [48].
Interest in the RNA binding properties of the KH2 domain has
been heightened by structural data suggesting that the human
I304N mutation maps to the RNA binding pocket present in KH
domains [49]. For example, the first structure of a KH domain
(Nova KH3) bound to its RNA ligand demonstrated that the RNA
binding pocket is supported by conserved hydrophobic amino
acids, one of which corresponds to the isoleucine mutated in the
I304N patient [50]. These observations have suggested that a key
defect in FMRP loss-of-function is the loss of sequence-specific
RNA binding, mediated through the FMRP KH2 domain [50,51].
Here we address these issues by generating and analyzing a mouse
(Fmr1
tm1(I304N)Drnl, termed here Fmr1
I304N) harboring the I304N
mutation. We find that the I304N mutation phenocopies Fmr1 null
mice. The mutant protein has lost polyribosome association and
RNA binding, and is present at reduced levels that vary with age,
but are particularly low at P14, during synaptogenesis. These
observations support the suggestion that sufficient levels of FMRP,
and/or its RNA binding activity, are critical for normal cognition.
Generation of the Fmr1
I304N mouse provides a new model for
understanding molecular defects in the disease, for screening
potential therapies, and heightens interest in identifying FMRP-
RNA interactions in the brain.
Results
Generation and characterization of Fmr1 I304N mice
To generate Fmr1
I304N mice we introduced the I304N mutation
into the endogenous mouse Fmr1 locus by homologous recombi-
nation (Figure 1A). An Fmr1 KH2 I304N targeting construct,
including a self-excising loxP-Auto-Cre-Neo
R-loxP (ACNF) cas-
sette which allows self-induced deletion of the selectable marker in
the male germline [52], was electroporated into embryonic stem
cells and 53 homologous recombinants were identified by
Southern blot (Figure 1B). Germline chimeras were bred to
generate Fmr1
I304N mice. These were bred for greater than 10
generations into both FVB and C57BL/6J backgrounds.
We examined Fmr1 mRNA expression in male FVB Fmr1
I304N
mice. Because the Fmr1 gene is on the X chromosome these mice
express only the I304N-mutant allele. Northern blot and
quantitative RT-PCR analysis showed that I304N Fmr1 mRNA
was expressed at wild type levels and was of the expected size in
both brain and testes (Figure 1C and 1D). Sequencing of RT-PCR
products from the Fmr1
I304N mice confirmed the presence of the
I304N mutation (data not shown).
Fmr1
I304N mice had no overt phenotype, were fertile with
normal litter sizes, and transmitted the mutant allele with the
expected X-linked Mendelian segregation ratios. Histological
examination of heart, spleen, liver, lung, kidney, adrenal glands,
stomach, intestines, muscles, diaphragm, bladder, and thymus of
Fmr1
I304N mice revealed no macroscopic abnormalities nor
microscopic lesions (data not shown). Further analysis focused on
the brain and testes, as both organs are affected in Fragile X
patients, and the I304N patient in particular. Histologic analysis of
cerebellum, cortex, hippocampus and testes revealed no defects
(Figure S1A, S1B, S1C, S1D, S1E, S1F, S1G, S1H, S1I, SIJ, S1K,
S1L, S1M, S1N, S1O, S1P), similar to Fmr1 null mice [53,54].
Macroorchidism of greater than 25 ml combined testicular
volume is present in more than 90% of adult males with Fragile X
syndrome [55], and was particularly severe in the I304N patient
whose testicular volume exceeded 100 ml [10]. We measured the
testicular weights of adult Fmr1
I304N mice compared to either WT
or Fmr1 null littermates. Macroorchidism was evident in Fmr1
I304N
mice compared to WT animals (12–28% increased weight), and
the most pronounced differences were evident in older animals
(Figure 2A). Testicular weight in Fmr1
I304N mice was similar to, but
surprisingly, no greater than that seen in FMR1 null mice
(Figure 2B; [53,54]). There was no significant difference in body
weights between Fmr1
I304N mice and wild type or Fmr1 null
littermates (Figure 2C and 2D). These observations indicate that
the I304N mutation in mice phenocopies the macroorchidism
evident in human patients, and suggests that the profound
macroorchidism evident in the I304N patient may result from a
combination of the I304N mutation and additional factors.
Behavioral analysis of I304N mice
Modeling the human behavior deficits seen in Fragile X
Syndrome in mouse models has proven challenging, although
some marked differences between Fmr1 null mice and normal
littermates have been characterized [56,57]. We compared
Fmr1
I304N and WT littermates in behavioral assays, blind to
genotype. We assessed a battery of 11 behavioral tests that are well
established measures of deficits in Fmr1 null mice [58,59]. These
Author Summary
Missense mutations in human genes provide valuable
insight into the genetic causes of disease. Fragile X
Syndrome (FXS), a common genetic cause of autism and
mental retardation, is usually caused by transcriptional
silencing of the FMR1 gene. The potential importance of
single patient with a missense mutation (I304N) in an
RNA–binding domain of the Fragile X protein, FMRP, has
been questioned in part because he has a confounding
liver disease. We introduced the I304N mutation into the
endogenous Fmr1 locus to create a mouse model of
Fragile X Syndrome. We find that this mutation results in
behavioral, electrophysiologic, and phenotypic features of
the disease, loss of binding to RNA targets in the brain, and
lower FMRP levels at a critical time during synapse
formation. We conclude that loss of RNA binding and
underexpression of FMRP are sufficient to cause the Fragile
X Syndrome.
An I304N Missense Mouse Model of FXS
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startle and prepulse inhibition, conditioned fear, pain sensitivity,
marble burying (as a measure of perseverative behavior), and
susceptibility to audiogenic seizure. Results in the Fmr1
I304N mice
were consistent with lower levels of anxiety and greater repetitive/
perseverative behavior (Table 1, Figure S2, and Text S1).
Importantly, one of the most robust phenotypes in Fragile X null
mice, increased susceptibility to audiogenic seizure, was evident in
18% of Fmr1
I304N mice but not in WT mice; these results are
comparable to or more severe than those reported in Fmr1 null
mice (see Text S1 for discussion). Taken together, our results
indicate that in 10 of 11 tests, Fmr1
I304N mice show similar
responses to those reported for Fmr1 null mice. Both are
hyperactive, have increased perseverative behavior and audiogenic
seizures, and reduced anxiety and startle reflexes relative to
normal mice.
I304N knock-in mice have altered synaptic plasticity in
hippocampus
Fmr1 null mice have defects in synaptic plasticity. The most
well-studied relates to metabotropic glutamate receptor-dependent
long term depression (mGluR-LTD) in hippocampal CA1 neurons
that normally requires de novo protein synthesis in dendrites. In
Fmr1 null mice, mGluR-LTD elicited by either an mGluR agonist
(DHPG) or electrical stimulation of Schaffer collateral inputs to
CA1 neurons (paired pulse low frequency stimulation (PP-LFS)) is
enhanced [11], and no longer requires protein synthesis [60,61].
We assayed the protein synthesis requirement for both chemically
Figure 1. Generation of the Fmr1 I304N knock-in mouse model. (A) The KH2-I304N Fmr1 targeting construct introduces an isoleucine to
asparagine mutation in exon 10. An Auto-Cre-Neo
R (ACNF) cassette for selection and auto-excision in the male germline was inserted in a non-
conserved region of intron 10. (B) Southern blot analysis of representative ES cells transfected with the I304N Fmr1 targeting construct. DNA from ES
cell clones was digested with BamHI and probed for recombination by Southern blot using a probe outside the targeting construct (dotted line in
(A)). The targeted allele, 2.7kb (clones 3, 4, 6–8), can be distinguished from the wild type locus, 9.6kb. (C) Brain (B) and testicular (T) mRNA from WT,
Fmr1 null (KO), and Fmr1
I304N (I304N) mice was probed with an in vitro transcribed radiolabeled RNA probe anti-sense to the 39UTR of Fmr1 and
visualized by Northern blot. b-actin mRNA was detected with an oligo probe. (D) RNA prepared from brain as in (C) was quantified by quantitative RT-
PCR with two sets of primers encompassing different regions of the Fmr1 mRNA, including primers spanning exons 2 to 3 (left panel) and primers
spanning exons 10 to 11 (right panel), and normalized to Gapdh and WT mRNA levels. Error bars reflect the standard deviation from three mice of
each genotype.
doi:10.1371/journal.pgen.1000758.g001
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slices prepared from Fmr1
I304N mice and their wild type
littermates. Pre-incubation with the protein synthesis inhibitor
anisomycin inhibited both DHPG (p=0.003) and PP-LFS
(p=0.003) induced LTD in wild type mice (Figure 3A and 3C),
but had no effect on the establishment of LTD in Fmr1
I304N mice
(Figure 3B and 3D). LTD magnitude in the absence of anisomycin
was not different between Fmr1
I304N and wild type littermates. We
also found no significant difference between wild type and Fmr1
null mice in these studies, consistent with the lack of enhanced
LTD in the I304N mice (see Discussion).
Finally, since the I304N patient is more severely affected than
typical Fragile X patients, we examined whether mGluR-LTD is
enhanced in the Fmr1
I304N relative to Fmr1 null mice. We
compared DHPG-elicited LTD measurements in Fmr1
I304N and
Fmr1 null littermates, and found that there was no difference in the
degree of LTD elicited (Figure 3E).
Taken together, given the degree of similarity in the phenotypes
between Fmr1
I304N and Fmr1 null mice, including their behavior,
macroorchidism and altered synaptic plasticity, we conclude that
the I304N mutation in FMRP is sufficient to cause symptoms of the
Fragile X Syndrome.We next used this mouse model to address the
mechanism by which this missense mutation in the KH2 RNA-
binding domain of FMRP results in the Fragile X phenotype.
I304N FMRP levels in the I304N mouse
We examined I304N-FMRP expression in the brain, testes, and
spleen by Western blot analysis. At 2 months of age, I304N-
FMRP was expressed at ,30% of normal levels in brain and
remained at ,30% of WT levels at 6 months of age (Figure 4A
and 4B). In younger mice (P14), WT FMRP levels were much
higher, while I304N-FMRP was expressed at levels only slightly
higher than in older mice, leading to a relatively larger difference
between WT and I304N FMRP levels in the second postnatal
week (,13% of the WT level; Figure 4A and 4B). We found no
evidence for a compensatory increase of the FMRP homologues,
FXR1P and FXR2P, in I304N mice (Figure 4C). I304N-FMRP
was also present at lower steady-state levels than the WT protein
in other tissues (,30% in testes and spleen at 6 months of age;
Figure 4D).
Decreased protein steady-state levels with normal mRNA levels
(Figure 1C and 1D) suggests that I304N-FMRP may either be
synthesized more slowly or turned over more rapidly. We analyzed
whether I304N Fmr1 mRNA was being translated by comparing
its distribution on polyribosomes with WT Fmr1 mRNA in P14
mice. Quantitative RT-PCR analysis of mRNA levels showed that
I304N Fmr1 and WT Fmr1 mRNA had similar distributions across
16 sucrose gradient fractions (Figure 4E). These observations
suggest that the lower I304N-FMRP levels do not relate to
Figure 2. Fmr1
I304N mice are macroorchid compared with WT littermates and have the same degree of macroorchidism as
Fmr1
tm1Cgr littermates. (A) Combined weights (W) of both testes of FVB.Fmr1
I304N mice (n=43) were compared with their wild type FVB littermates
(n=34). For statistical analysis, litters of similar ages were grouped together and data were subject to student’s t-test. Age 17–19 days, weight (W) of
the Fmr1
I304N mice=0.03160.003g (n=6), W(WT)=0.04260.007g (n=3), p.0.05; age 31–33 days, W(Fmr1
I304N)=0.13060.009g (n=6),
W(WT)=0.13460.008g (n=6), p.0.05; age 65–79 days, W(Fmr1
I304N)=0.22460.005g (n=14), W(WT)=0.19560.005 (n=13), *p,0.03; age 117–
119 days, W(Fmr1
I304N)=0.26360.006g (n=11), W(WT)=0.23460.010 (n=6), *p,0.03; age 196–233 days, W(Fmr1
I304N)=0.24360.014g (n=6),
W(WT)=0.19060.007 (n=6), **p,0.001. (B) Combined weights (W) of both testes of FVB.Fmr1
I304N mice (n=32) were compared with their FVB.Fmr1
null littermates (n=28). (C) Body weights from the same mice in (A). (D) Body weights from the same mice in (C).
doi:10.1371/journal.pgen.1000758.g002
An I304N Missense Mouse Model of FXS
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mutant protein, particularly in younger mice.
I304N FMRP function in the I304N mouse
FMRP associates with polyribosomes in tissue culture cells
[23–25] and in brain [26–28], suggesting that the protein may
regulate mRNA translation. In contrast, in lymphoblastoid cell
lines derived from the I304N patient, and in cells transfected with
an EGFP-tagged I304N-FMRP reporter construct, mutant FMRP
no longer associates with polyribosomes [25,62]. To examine
whether the I304N mutation affected endogenous FMRP-
polyribosome association in the brain, we examined the
distribution of the mutant protein in the brains of Fmr1
I304N mice.
A254 traces of polyribosomes separated by sucrose density
centrifugation revealed no difference between wild type and
Fmr1
I304N mouse brain, suggesting that global translation status
was normal in the mutant mice (data not shown). However,
I304N-FMRP was largely dissociated from polyribosomes in
mouse brain (Figure 5A), and there was a reciprocal increase in
I304N-FMRP present in lighter polysome fractions (Figure 5B).
We also found that the I304N mutation in FMRP does not
significantly affect FXR1P or FXR2P polyribosome association in
mouse brain (Figure 5A), suggesting that their polysome-
association is not FMRP-dependent. These results are consistent
with previous findings in patient lymphoblastoid cell lines [25],
and suggest that the I304N mutation impacts the normal function
of FMRP on polyribosomes.
The endogenous I304N-FMRP complex is abnormally
small due to loss of RNA binding by mutant FMRP
It has been suggested that the I304N mutation renders FMRP
incapable of forming normal mRNP complexes in cultured cells
[25]. We analyzed endogenous WT or I304N-FMRP particle size
by Superose 6 gel filtration of mouse brain cytoplasmic extracts
prepared in EDTA to release ribosomal subunits from mRNA.
Wild type FMRP was found in the void volume of the Superose 6
column, indicating that FMRP is normally present in a complex of
greater than 40,000 kDa (Figure 6A, upper left panels). In
contrast, the majority of I304N-FMRP was shifted into a smaller
complex eluting at approximately 100–300 kDa (Figure 6A, lower
left panels). This complex may correspond to a small (,440kD)
I304N complex observed in I304N patient-derived lymphoblastoid
cells [25]. Mutant I304N-FMRP had no significant effect on the
apparent size of FXR1P or FXR2P complexes (Figure 6A, left
panels).
To assess whether the loss of I304N-FMRP from larger
complexes might result from a loss of protein-RNA interaction,
we treated brain cytoplasmic extracts with excess RNase prior to
Superose 6 gel filtration. Under these conditions, the WT FMRP
complex size was reduced to the size of the I304N-FMRP complex
(Figure 6A, upper panels, compare fractions 4–5 and 13–14), but
the I304N complex did not change in apparent size (Figure 6A,
lower panels); similar results were seen when EDTA was omitted
from the lysis buffer (data not shown). This suggests that relative to
FMRP, the I304N-FMRP in mouse brain has lost most or all of its
ability to associate with RNA. We cannot rule out binding to small
RNAs that would not affect migration on Superose 6 columns
(those less than ,200 nucleotides (66 kDa), which we estimate
would shift Superose 6 migration). We note that a small amount of
I304N-FMRP is present in the void volume in an RNase sensitive
manner, which could be due to heterodimerization with other
RNA binding proteins or residual RNA interactions from other
FMRP RNA binding domains.
Mouse brain I304N FMRP retains some functional
domains
To assess whether the I304N protein retains reported biologic
activities in vivo, we evaluated whether it was competent to interact
with protein partners. We first compared the size of the RNase-
treated I304N FMRP complex with that of denatured, recombi-
nant I304N-FMRP added to mouse brain extract by Superose 6
gel filtration. Endogenous mouse brain I304N-FMRP was found
in a complex significantly larger (fractions 13 and 14) than the
I304N recombinant protein added to the same extract (fraction
15), suggesting that the native I304N protein in brain is capable of
protein interactions independent of RNA binding (Figure 6B).
FMRP was previously found to heterodimerize with its two
autosomal homologs, FXR1P and FXR2P, by yeast two-hybrid
assays [46]. In vitro studies indicated that I304N FMRP retains the
ability to heterodimerize with FXR1P and FXR2P [63]. We
analyzed the ability of endogenous I304N-FMRP to heterodimer-
ize in mouse brain by immunoprecipitating I304N protein and
assaying for co-precipitating FXR1P and FXR2P by Western blot.
These experiments demonstrated that FXR1P and FXR2P co-
precipitated with WT and I304N-FMRP, but not in control IPs
from FMRP null brains (Figure 7A). Less FXR1P and FXR2P are
co-precipitated by I304N-FMRP as compared with wild-type
FMRP, but this is likely to be accounted for by the lower FMRP
levels in the I304N mutant mouse (Figure 4, Figure 7B, third
panel).
In vitro RNA selection studies identified a kissing complex RNA
that is bound with high affinity by the FMRP KH2 domain [51]
and a G-quartet RNA ligand for the C-terminal RGG–type RNA
binding domain [64,65]. Recombinant I304N-FMRP produced
in insect cells has been shown to bind to G-quartet RNA, but not
the kissing complex RNA [51]. We therefore examined
endogenous I304N-FMRP in mouse brain to determine whether
it recapitulated these RNA binding properties. Radiolabeled G-
quartet or kissing complex RNA synthesized by in vitro
transcription was added to mouse brain lysates, UV-crosslinked,
Table 1. Tabulation of behavioral test summary and
comparison with historical findings on Fmr1
tm1Cgr null mice.
Behavioral tests I304N vs WT KO vs WT
Activity in open field qq
Rearing in open field - -
Anxiety in open field QQ
Anxiety in light/dark QQ
Time to go to dark - -
Acoustic startle response QQ
Pre-pulse inhibition - - (q*)
Conditioned fear - -
Hotplate sensitivity to pain QQ
Marble burying qq
Audiogenic seizure 18% Reported*
Assays marked with an asterisk indicate areas of discrepancy with the literature.
Prior studies of prepulse-inhibition [68] found a trend toward a decrease in PPI,
as seen here, although others have reported it to be increased. The audiogenic
seizure experiments were performed on 2–3 month old I304N mice and WT
littermates, and the Fmr1 null mice have not previously been reported to
display audiogenic seizures beyond the age of 7 weeks in a C57Bl/6
background [89] although they consistently display audiogenic seizures at
younger ages.
doi:10.1371/journal.pgen.1000758.t001
An I304N Missense Mouse Model of FXS
PLoS Genetics | www.plosgenetics.org 5 December 2009 | Volume 5 | Issue 12 | e1000758immunoprecipitated with an antibody against FMRP and
crosslinked RNA detected by autoradiography after SDS-PAGE.
A radiolabeled FMRP:RNA complex was seen specifically in the
immunoprecipitate of the I304N-FMRP extract crosslinked to
the G-quartet RNA, but little or no I304N protein was
crosslinked to kissing complex RNA (Figure 7B). When
compared with the wild type FMRP, the reduced radioactive
signal from G-quartet RNA crosslinked to the I304N-FMRP in
mouse brain was consistent with lower I304N-FMRP levels in the
knock-in mice (Figure 7B, third panel). Point mutants of G-
quartet or mutant kissing complex RNAs, which are not bound
by recombinant FMRP in vitro [51,64] did not crosslink to either
endogenous wild type or I304N-FMRP in mouse brain (data not
shown). Taken together, these data indicate that I304N-FMRP in
mouse brain retains some normal properties, as it is competent to
bind both protein and, via its RGG-domain, to bind G-quartet
RNA. RGG-domain RNA binding to RNA over 200nt is not
evident in the I304N mouse, suggesting either that it plays a
minor or dependent role to KH2 binding to large RNAs.
Therefore a major biochemical defect in the Fmr1
I304N mouse is
the loss of KH2-dependent RNA binding. While other interpre-
tations cannot be ruled out, including the loss of KH2-dependent
interaction with a protein partner, taken together our data
s u g g e s tt h a tt h er e s u l t i n gl o s s of polysome association and,
presumably, proper regulation of translation of FMRP mRNA
targets, is most likely to contribute to the phenotype of the
Fmr1
I304N mouse.
Discussion
The Fragile X Syndrome is usually caused by a triplet repeat
e x p a n s i o ni nt h e5 9UTR of the FMR1 gene leading to
transcriptional silencing of the FMR1 mRNA and failure to
produce the FMRP protein product. A severely affected patient
has offered possible insight into a key function of FMRP, as he
harbors a missense (I304N) mutation in the KH2 RNA binding
domain [10]. The I304N mutation has previously been shown to
abrogate RNA binding of similar KH-type RNA binding
domains in vitro, suggesting that the disease symptoms in this
patient are caused by the loss of FMRP KH2 domain sequence-
Figure 3. Protein synthesis-independent mGluR-LTD in Fmr1
I304N mice. Evoked extracellular field potentials (FPs) from CA1 of acute slices
from 30–90 day old wild-type and B6.Fmr1
I304N littermates are plotted as a percent of baseline (pre-DHPG or PP-LFS). (A,B) Anisomycin inhibits DHPG-
induced LTD in wild-type littermates, but has no effect in B6.Fmr1
I304N mice (*; p=0.02). (C,D) Anisomycin inhibits synaptically induced LTD (with PP-
LFS; *; p=0.004) in wild type mice, but not B6.Fmr1
I304N mice. The magnitude of LTD between wild type and Fmr1
I304N mice is not different under
control conditions, but is enhanced in the presence of anisomycin (ANOVA and subsequent Fisher PLSD; p,0.05). (E) There is no difference in the
degree of LTD elicited by DHPG stimulation between B6.Fmr1
I304N mice and their Fmr1 null littermates.
doi:10.1371/journal.pgen.1000758.g003
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the I304N mutation abolishes RNA binding in neurons nor that
this mutation alone causes the Fragile X symptoms in this
individual patient, as his clinical picture is complicated by an
unrelated familial liver disease, X-linked liver glycogenosis due to
phosphorylase kinase deficiency. To address these issues, we have
generated and analyzed a mouse model harboring the I304N
mutation in the endogenous Fmr1 locus. These mice exhibit
many of the phenotypic (macroorchidism), electrophysiologic
and behavioral changes of Fmr1 null mice, and thereby indicate
that the I304N mutation is sufficient to phenocopy transcrip-
tional silencing of the Fmr1 gene. Surprisingly, we find both that
FMRP RNA binding is lost in the brains of these mice,
establishing a connection between KH2 RNA binding and the
neurologic disorder, and that protein levels are markedly reduced
at P14, a time of synaptogenesis in the neocortex and other brain
areas.
I304N mice have a Fmr1 null-like phenotype
Behavioral changes in the Fmr1 null mouse relative to either
wild-type or mutant littermates have been well described. We
compared the Fmr1
I304N mouse to wild-type littermates on the
same background and using many of the same assays employed for
extensive behavioral testing of the Fmr1 null mouse, the Fxr2 null
mouse, double knockout of both Fmr1 and Fxr2, and a mouse
overexpressing human FMRP from a transgenic YAC construct
[53,66–69]. In most cases the phenotype of the KH2 mutant
Fmr1
I304N mice was similar to the previously published phenotype
of the Fmr1 null mice, including increased audiogenic seizure rates,
decreased acoustic startle responses, and assays indicating greater
exploratory behavior, decreased anxiety responses and increased
perseveration. Our results measuring PPI, while consistent with
Fmr1 null mice assessed in our laboratory [68], differed from those
of some investigators [70,71]; it is possible that strain differences
may account for some of this discrepancy. In summary, our
Figure 4. Expression of FMRP in Fmr1
I304N and WT littermates. (A) 50 ug of brain lysate from three Fmr1
I304N mice and three wild type
littermates at P14, 2 mo, and 6 mo of age, were analyzed by Western blot for steady state FMRP expression using the anti-FMRP C-terminus antisera
ab17722 (Abcam) and gamma-tubulin as a loading control. (B) Signal was quantified by chemiluminescence using Versadoc imaging and the
percentage of I304N-FMRP signal compared to wild type FMRP is indicated. Error bars reflect the standard deviation of three mice. This experiment
has been repeated several times and with different antibodies to FMRP (Chemicon ab2160 (1C3), 2F5 [84], and 7G1-1 [85] with consistent results. (C)
50 ug of brain lysate from P14 mice of the indicated genotype (littermates) was analyzed for expression of FMRP with ab17722, FXR1P, FXR2P, and
gamma-tubulin. (D) 50ug of testes or spleen lysate from the same animals at P60 was analyzed in the same way with ab17722, and normalized to
Hsp90 levels. (E) Brain lysates for polyribosome analysis were prepared from Fmr1
I304N mice and WT littermates, and fractionated over linear 20%–
50% sucrose gradients. The levels of Fmr1 mRNA and Gapdh mRNA were quantified in each fraction by quantitative RT–PCR using the DDCt method.
An A254 absorption profile from one of the WT mice is shown in the upper panel and the 80S monosome and polyribosomes are indicated. Other
gradients were indistinguishable within a WT and I304N littermate pair. Relative mRNA level in each fraction was plotted as a percentage of total
mRNA to illustrate its distribution over the polyribosome gradient. Error bars reflect three technical replicates from a single littermate pair. The
experiment has been repeated with additional littermate pairs, but cannot be plotted on one graph due to variable fraction collection between
experiments. Representative graphs are shown.
doi:10.1371/journal.pgen.1000758.g004
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I304N mice indicate that they show
abnormalities in the same tests, in the same direction, and to
similar levels in all assays previously performed in our laboratory
(Table 1), strongly supporting the conclusion that the I304N
mutation is sufficient to phenocopy loss of the Fmr1 gene.
Metabotropic glutamate receptor-dependent LTD is a hippo-
campal synaptic plasticity paradigm that relies on rapid protein
synthesis in dendrites [72]. Previous work in the Fmr1 null mouse
demonstrated that LTD is enhanced and independent of new
protein synthesis and translational regulators, such as ERK and
Homer [11,13,16,60,61,73]. From these studies, it was suggested
that FMRP regulates the translation of the dendritic mRNAs
required for mGluR-LTD expression. Here we demonstrate that
LTD induced with either chemical or synaptic stimulation is
independent of protein synthesis in the Fmr1
I304N mice, recapit-
ulating the Fmr1 null phenotype (Figure 3). This suggests that
FMRP must interact with polyribosomes or kissing-complex RNAs
for normal mGluR-LTD regulation. Alternatively, the effects on
LTD could be due to a hypomorphic expression of I304N-FMRP.
It is unclear why we did not detect alterations in the magnitude of
LTD between Fmr1
I304N mice and wildtype littermates or Fmr1
null littermates as demonstrated previously [13,16,60,61]. We also
found no significant enhancement of LTD between wild type and
Fmr1 null littermates in the current study. This may be due to the
fact that older mice were used in this study (40–90 day) than in
previous work (21–35 day) or other factors such as stress levels,
which are known to impact mGluR-LTD magnitude [74]. Subtle
genetic background differences may also play a role. Notably, the
independence of LTD on protein synthesis, as seen here in the
Fmr1
I304N mice appears to be a more robust and reproducible
phenotype in Fmr1 null mice in comparison to enhanced LTD
magnitude [73,75].
Macroorchidism is a profound clinical finding in postpubertal
Fragile X patients, affecting more than 90% of adult male patients
[55]. In mouse models, the Fragile X null mouse has a 20–25%
increase in testicular size [53,54,76] which is rescued by a wild
type human FMRP transgene [53]. The Fmr1
I304N mice display
the same degree of macroorchidism as their null counterparts, and
this increases with age, as in the Fmr1 null mice [54] and in the
human patients [6], supporting the conclusion that the Fmr1
I304N
mutation is sufficient to phenocopy the Fragile X Syndrome.
Biochemical analysis of I304N mice
Steady-state levels of endogenous I304N-FMRP were found to
be decreased relative to WT FMRP. While all of the characteristic
isoforms of FMRP are observed in the Fmr1
I304N tissues, they are
expressed at lower levels than in wild type littermates. The post-
transcriptional reduction in steady state levels of I304N-FMRP
compared with mRNA levels has also been observed in two lines of
I304N-FMRP BAC transgenic mice (data not shown), and in
I307N-dfmr1 flies, which have the analogous mutation to I304N-
FMRP in mammals [77]. Taken together, these data suggest that
decreased protein levels are intrinsic to the mutation rather than a
result of our genetic manipulation.
Lower steady state levels of I304N FMRP in brain and testes are
surprising in light of previous data demonstrating that I304N
FMRP is expressed at normal levels in EBV transformed
lymphoblastoid cells from the patient with the I304N mutation
[25] and may be due to the fact that a different cell type was
studied or that EBV transformation altered normal FMRP
expression. We find that steady state levels of I304N-FMRP are
too low in cultured primary neurons to permit standard pulse-
chase immunoprecipitation experiments to quantify I304N FMRP
synthesis and turnover (data not shown). Another means of
assessing FMRP synthesis is to analyze the distribution of its
mRNA on polyribosome sucrose gradients. We have shown that
I304N-Fmr1 mRNA has a normal profile on polyribosomes
Figure 5. Endogenous I304N-FMRP is dissociated from polyri-
bosomes in mouse brain. (A) Mouse brain cytoplasmic extracts from
WT and Fmr1
I304N littermates (second postnatal week) were separated
on 20–50% linear sucrose gradients. The positions of the 80S
monosome and polyribosomes are indicated on the A254 profile from
each gradient (top panel). FMRP (detected with either 17722 or 7G1-1
antibody, to insure no crossreactivity with FXR1P and FXR2P)), FXR1P
(ML13 antibody), and FXR2P (1G2 antibody) distributions were analyzed
by Western blot. Ribosomal protein S6 (S6P) distribution confirms the
integrity of the polyribosomes. (B) Quantification of chemiluminescence
by Versadoc imaging of the Western blot of FMRP distribution from WT
and Fmr1
I304N littermates; values reflect the percentage of FMRP
present in each fraction relative to total FMRP in the gradient. Errors
bars reflect the standard deviation of the technical replicates.
Quantification of this data revealed that very little wild type FMRP
was present in fractions containing less than 2 ribosomes per transcript
(fractions 1–5) and more than 55% was present on heavy polyribo-
somes (fractions 9–13), while 44% of total I304N-FMRP was in the
corresponding light fractions (1–5) with a corresponding loss from the
heavy polyribosomes. The experiment was repeated multiple times
with additional littermate pairs with very similar results.
doi:10.1371/journal.pgen.1000758.g005
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decreased protein synthesis is not likely to account for decreased
protein levels. It has been reported that FMRP can bind a G-
quartet motif in the coding sequence of its own mRNA, inhibiting
its translation [65]. However, we find no evidence to support the
consequent prediction that in the I304N mouse there would be an
increase in translation of the I304N-Fmr1 mRNA. Taken together,
it seems most likely that the observed decrease in I304N protein
levels is due to increased turnover of the mutant protein.
Interestingly, the decrease in I304N FMRP levels is much more
pronounced in mice at P14, relative to older mice (Figure 4A and
4B). This correlates with the observation that there are transient
alterations in the morphology of dendritic spines in Fmr1 null mice
[19]. This suggests that the biochemical defect present in I304N
FMRP may be compounded by a decrease in its levels during
synaptogenesis, and that the phenotype may result from a
combination of these effects.
I304N FMRP is defective in polyribosome association and
RNA binding
Several attempts have been made to assess the effect of the
I304N mutation on FMRP RNA binding and function. Recom-
Figure 6. Endogenous I304N-FMRP is in an abnormally small and RNase resistant complex. (A) The migration of standards including blue
dextran for the void volume, and proteins of 669, 440, and 67 kDa used to calibrate the Superose 6 3.2/30 column are shown. Brain lysates were
prepared from WT and Fmr1
I304N littermates (P22), treated with EDTA to disrupt polyribosomes, and treated with or without an overdigestion with
RNases as indicated, and applied to a Superose 6 column sequentially. Two gradients for each condition were pooled to obtain enough material from
eluted fractions for Western blot. Column fractions were TCA precipitated and Western blotted for wild type or I304N-FMRP (1C3), FXR1P (ML13),
FXR2P (1G2), Nova (human patient antisera) and hsp90. (Upper left) The wild-type FMRP mRNP complex eluted in the void volume of the column
(fraction 4) corresponding to a size of .40,000 kDa, as do most of FXR1P and FXR2P. FXR2P is shown by the upper band (arrow) as the FMRP blot was
reprobed with 1G2 without stripping. (Lower left) I304N-FMRP is in a much smaller complex of 100–400 kDa (fractions 13 and 14). Most of FXR1P in
the Fmr1
I304N lysate remains in the void volume though there is a small increase in fractions 11–14. FXR2P (arrow) remains in the void volume. (Upper
right) After complete RNase A and T1 digest, the wild type FMRP RNase-resistant complex migrates at the size of the native I304N FMRP complex
(fractions 13 and 14) as does FXR1P. The RNase-resistant FXR2P complex migrates in fractions 12 and 13. (Lower right) The I304N-FMRP complex does
not shift in apparent size after RNase treatment. FXR1P and FXR2P shift in a similar way in the Fmr1
I304N lysate as they do in the presence of wild-type
FMRP. In all conditions, hsp90 migrates in fractions 11 and 12. An irrelevant RNA binding protein, Nova, runs as several isoforms, two of about 68 kDa
and three of approx. 52 kDa. Their migration is identical in Fmr1
I304N and wt lysates (fraction 12–14), and they are shifted to smaller size after RNase
treatment in both lysates (fraction 13–15). (B) The RNase-resistant complex containing I304N-FMRP is larger than a monomer of I304N-FMRP alone.
I304N fusion protein was denatured, added to a mouse brain lysate, and run on the same system to determine the migration of a monomer of I304N-
FMRP. It was detected in fraction 15–16 using an anti-HisTag antibody.
doi:10.1371/journal.pgen.1000758.g006
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decreased binding to ribohomopolymers or in vitro-selected RNA
ligands [40,51,78]. Other studies have found that recombinant
I304N FMRP produced in insect cells retained some ribohomo-
polymer binding, but with decreased binding to poly-U [79]. The
I304N mutation in FMRP abrogates binding to high affinity in vitro
selected KH2 target RNA ligands (kcRNA) but not RGG target
(G-quartet) RNAs, as assessed with both full-length FMRP and
isolated RNA binding domains [51,64], indicating that KH-
specific RNA interactions are lost in the I304N mutant in vitro.
However, in lymphoblastoid cell lines derived from I304N
patients, some I304N-FMRP was able to be captured on oligo-
dT columns, which was interpreted as showing that I304N mRNA
association was intact [25]. We also find that some I304N FMRP
is retained in the void volume of the Superose 6 column in an
RNase-dependent manner (Figure 6), which may be due to
heterodimerization with FXR1/2P (Figure 7A; [63]), or to residual
RNA binding from the RGG domain (Figure 7B).
The conclusion that I304N FMRP KH2 domain fails to bind
RNA in vivo is consistent with structural studies of several RNA-
binding proteins suggesting that this mutation should affect RNA
binding. Most studies of isolated protein domains (vigilin KH6,
FMRP KH1, and Nova-2 KH3) have predicted that the I304N
mutation results in an unfolded KH domain, which would be
expected to lead to loss of specific RNA binding. However, other
KH domains harboring mutations analogous to I304N are
correctly folded, including the Drosophila homolog of FMRP
(dfmr1p) tandem KH1-KH2 [80], and BBP/SF1, in which RNA
binding is specifically lost [81]. The first co-crystal of a KH
domain—RNA complex (Nova-RNA) [50], as well as a subse-
quent review of structures [49], suggest that mutation of the
conserved hydrophobic amino acid analogous to Ile-304 must
decrease RNA binding affinity. While a consensus from these KH
domain:RNA structures is that the isoleucine mutation disrupts
KH:RNA interactions, FMRP has multiple RNA binding
domains, so that RNA binding by the full-length protein may
not be abrogated despite loss of KH-dependent interactions. This
is consistent with our observation that I304N-FMRP in mouse
brain fails to crosslink to kcRNA, but retains other activities,
including the ability to crosslink to G-quartet RNA and to
heterodimerize with FXR1P and FXR2P (Figure 7). While we
show that the RGG box in the I304N-FMRP is still competent to
bind its high affinity in vitro-selected (G-quartet) RNA ligand, it
appears from the Superose 6 analysis that I304N-FMRP has lost
most of all of its RNA interactions in vivo. We propose that RNA
binding by the other RNA-binding domains of FMRP may be
hierarchical, such that the KH2 domain must make proper RNA
interactions for subsequent G-quadruplex binding by the RGG
box to occur. Taken together these observations suggest that the
I304N-FMRP mutation leads to a global loss of RNA binding in
vivo, and suggest that identification of FMRP KH2-RNA targets
will be of great interest.
I304N FMRP does not appear to have a dominant
negative effect
The severity of Fragile X symptoms reported in the I304N
patient has led to the hypothesis that I304N-FMRP might have a
dominant negative effect on its autosomal paralogs, FXR1P and
FXR2P, decreasing any functional redundancy present in the
absence of FMRP. We do not detect any evidence for this as the
expression levels, polyribosomal association and mRNP complex
sizes of FXR1P and FXR2P are unchanged in the Fmr1
I304N
mouse brain relative to wild type littermates. At the same time, we
find that mutant protein levels vary with age, such that they are
reduced (by two-thirds) in adult mice, but are even more markedly
reduced at P14, a time when synaptogenesis is occurring in many
areas of the mouse brain, including the forebrain and cerebellum.
This finding suggests that loss of FMRP activity, including but not
necessarily limited to KH2 RNA binding, may play a critical role
in leading to the synaptic defects evident in the mouse, and,
presumably, in human patients.
In addition, we find that macroorchidism in Fmr1
I304N mice,
while pronounced compared with wild type littermates, is no more
severe than in Fmr1 null littermates. mGluR-dependent LTD in
Fmr1
I304N mice is equivalent to that in Fmr1 null littermates, but
not enhanced. Behavioral assays give little or no indication of a
more severe behavioral deficit than the Fmr1 null mouse. Taken
together, these findings suggest that Fmr1
I304N mice have an Fmr1
Figure 7. I304N-FMRP retains the ability to heterodimerize and
bind G-quartet RNA. (A) Brain lysates for IP were prepared from WT,
Fmr1
I304N (I304N) and Fmr1 null (KO) mice, and FMRP IPed with 7G1-1
antibody. Immunoprecipitates were probed by Western blot for co-IP of
FXR1P (left panel) and FXR2P (right panel). Approximately 5% of the
input lysate was run in lane 1. (B) Brain extracts from adult WT,
Fmr1
I304N (I304N), and Fmr1 null (KO) mice were incubated with
radiolabeled RNA (G-quartet RNA (left panel) and kissing complex RNA
(middle panel)) generated by in vitro transcription in the presence of
32P-UTP. Samples were UV crosslinked (XL), immunoprecipitated with
FMRP specific 7G1-1 antibody, run on SDS-PAGE gels, transferred to
nitrocellulose and exposed by phosphorimaging to detect radiolabeled
RNA crosslinked to FMRP (open arrowhead). The same immunoprecip-
itates (IP) were probed for FMRP by Western blot using antibody 2F5
(right panel, filled arrowhead).
doi:10.1371/journal.pgen.1000758.g007
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Supporting this, the analogous I307N mutation in Drosophila
dfmr1 results in a partial loss of function phenotype [77]. We
propose that the severe Fragile X symptoms, including IQ below
20, lack of verbal communication, and impressive macroorchidism
observed in the I304N patient may be a result of selection bias, in
that this patient may have been selected for further gene
sequencing precisely due to the severity of his Fragile X
phenotype. Because screening for Fragile X Syndrome is currently
performed by PCR for the CGG repeat expansion, negative results
may be classified as nonsyndromic mental retardation or
nonspecific developmental delay, in the absence of characteristic
features of Fragile X Syndrome.
Although we cannot exclude that the severity of the I304N
patient’s symptoms may have contributions from other genetic
factors, including exacerbation by his familial liver disease, we note
that none of the patient’s other 29 relatives affected by liver
glycogenosis have mental retardation, or the neurologic and
phenotypic defects found in the Fragile X patient. We cannot rule
out the possibility that the I304N patient might express elevated
I304N FMRP levels such that a dominant negative action
exacerbates his symptoms. Nonetheless, based on our finding of
decreased I304N FMRP in the mouse model and similar results
from the I307N mutation in dfmr1 [77], we infer that it is most
likely that the I304N patient has lower steady state levels of
neuronal I304N-FMRP.
A new mouse model for the Fragile X Syndrome
The Fmr1
I304N mouse provides an additional mouse model for
the Fragile X Syndrome. The most widely used model for Fragile
X Syndrome, the Fmr1
tm1Cgr mouse, is a complete null due to the
insertion of the neo cassette in exon 5 of the Fmr1 gene. By causing
loss of FMRP expression, the Fmr1
tm1Cgr mutation largely
recapitulates the human Fragile X Syndrome at the protein level.
Nonetheless, the CGG repeat expansion, present in most human
patients, is not replicated in the Fmr1
tm1Cgr null mouse, and the
repeat may contribute in unknown ways to the disorder (soaking
up CGG DNA binding proteins, or interfering with expression of
transcripts present on the other DNA strand [8,9]). In addition,
the Fmr1
tm1Cgr null mouse still contains a neo-expression cassette,
which has been documented in some cases to affect expression of
neighboring genes and lead to confounding phenotypes. Thus as a
model system, the I304N mouse genocopies the human I304N
patient better than the null mouse genocopies the CGG repeat
expansion. However, we appreciate that human deletions and the
point mutation patient, to the extent that they share all the
symptoms of Fragile X Syndrome, argue against the CGG repeat
expansion itself playing a significant role in the disease, and that
the I304N mutation is limited in clinical significance relative to the
CGG expansion.
The I304N mutation causes defective KH2-mediated RNA
binding in neurons, and decreased FMRP levels, particularly in
younger animals. The loss of KH2 function accounts for the
dissociation of the protein from brain polyribosomes. We propose
that this leads to a loss of proper translational control of FMRP
mRNA targets, which in turn leads to the cognitive and behavioral
deficits observed in the Fragile X Syndrome. Our observations
underscore the importance of identifying FMRP KH2 RNA
ligands in the mouse brain to understand the pathogenesis of the
disease. Identification of a reliable and comprehensive set of in vivo
RNA targets will benefit from use of the Fmr1
I304N mouse model,
in conjunction with the Fmr1 null [54], Fmr1 conditional knockout
[82], and FMR1 YAC transgenic mice [53] for validation and
functional studies. Finally, trials of potential clinical treatments can
be tested on the Fmr1
I304N mice, since they provide an additional
animal model in which rescue of phenotype can be measured.
Materials and Methods
Generation of targeted Fmr1 I304N knock-in mutation
A genomic clone encoding the murine Fmr1 gene was isolated
from a BAC library derived from a 129 mouse (ES-129/SvJ BAC
library, clone address 217I21, Incyte Genomics). To generate an
Fmr1 KH2 I304N targeting vector, a 7.2 kb BamHI-XhoI 59
homology arm spanning intron 5 to intron 9 and a 1.9kb XhoI-
KpnI fragment spanning intron 9 to intron 11 (including exon 10
where the I304N mutation occurs, and a 39 homology arm (1.3kb))
were cloned into pBluescriptIISK(+) (Stratagene). PCR mutagen-
esis of the XhoI-KpnI fragment introduced the I304N mutation in
exon 10 to change the sequence CTG(Leu) ATT(Ile) CAA(Gln) to
CTT(Leu) AAC(Asn) CAG(Gln)). The two wobble mutations were
introduced to create a new HindIII site for genotyping and to
facilitate PCR genotyping with a mutant-specific primer. A new
XbaI site was also generated in the middle of intron 10 in a region
that was not conserved between the mouse and human FMR1
genes. The loxP-Auto-Cre-Neo
R-loxP (ACNF) cassette (from Dr.
Peter Mombaerts) was inserted in the new XbaI site. Finally, the 59
homology arm and the XhoI-(I304N)-(ACNF)-KpnI fragment
were ligated together into the pBluescript plasmid. The plasmid
was linearized with NotI and used to electroporate ES cells at the
Transgenic Services Laboratory at The Rockefeller University.
Genomic DNA from individual colonies was digested with BamHI
and screened by Southern blot analysis. The Southern probe
overlapping exon 12, which has no corresponding sequence in the
mouse Fxr1 or Fxr2 gene [83], distinguished the targeted allele,
2.7 kb, from wild type locus, 9.6 kb. Correctly targeted clones
were selected for blastocyst injection and transferred to pseudo-
pregnant females, from which germline chimeras were obtained.
Fmr1
tm(I304N)Drnl (Fmr1
I304N) mice were bred greater than 10
generations into FVB and C57BL/6J backgrounds to generate the
congenic strains FVB.Fmr1
I304N and B6.Fmr1
I304N. To generate
wild-type (wt) and Fmr1
I304N mutant littermates on either
background, Fmr1
I304N/+ heterozygous (het) females were bred
with wild-type (wt) males of the same background and male
offspring were used for experiments. To generate Fmr1
I304N and
Fmr1 null littermates Fmr1
I304N/null het females were bred with wt
male mice and male offspring used.
RNA preparation
RNA from mouse tissues or polyribosome fractions was
extracted using Trizol or Trizol LS Reagent, respectively,
according to manufacturer’s instructions (Invitrogen). 10ng of in
vitro translated luciferase RNA was spiked into each polyribosome
fraction as a control for RNA recovery. Chloroform:isoamyl
alcohol (49:1) was added, samples spun at 15min at 12,0006g, the
aqueous phase collected and precipitated with ethanol at 220uC
overnight. RNA was pelleted at 20,0006g for 20min at 4uC,
washed with 75% ethanol, and dissolved in water. RNA was then
RQ1 DNase (Promega) treated at 37uC for 1hr and underwent a
second round of phenol-chloroform extraction and ethanol
precipitation.
Northern blots
Northern blots were performed following the NorthernMax-Gly
protocol (Ambion). Briefly, 30ug of brain RNA and 10ug of testes
RNA were denatured with Glyoxal load dye at 50uC for 30min
and then were separated on a 0.8% agarose gel in 16Gel Prep/
Gel Running buffer. RNA was transferred to a GeneScreen Plus
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32P-
labeled Fmr1 probe (see below) was hybridized to the membrane at
68uC for 2 hrs in QuikHyb hybridization solution (Stratagene).
b-actin probe was hybridized at 42uC for 1hr in ULTRAhyb-
Oligo solution (Ambion). Membranes were then washed with 26
SSC, 0.1% SDS and 0.16SSC, 0.1% SDS at room temperature.
Radiolabel was detected and quantified by PhosphorImager
(Bio-Rad).
Fmr1 probe, complementary to the 39UTR, was synthesized by
in vitro transcription with P
32-a-UTP using the MAXIscript kit
(Ambion) according to the manufacturer’s protocol. Template
DNA for transcription was generated using a reverse primer that
included the T7 promoter sequence (underlined).
F:59TCAGCAGTATGTTTCAGTCTTTCGG 39
R:59TAATACGACTCACTATAGGGGAGAGTTTTCAAA-
GTTGAAATTCGTCATCAGG 39
A 20nt long DNA anti-sense probe against b-actin exon 4 was 59
end labeled with
32P-ATP with T4 polynucleotide kinase (NEB)
and used for Northern blots.
Histopathology and testicular measurement
Histopathology analysis was performed by the Rockefeller
University Genetically Engineered Mouse Phenotyping core
facility. Four male FVB.Fmr1
I304N mice, five male FVB.Fmr1 null
littermatesand four FVBwild-type mice weresacrificedat 10 weeks
of age and tissues fixed in 10% formalin overnight and embedded
in paraffin blocks. Tissue sections were deparaffinized, rehydrated,
stained with hematoxylin & eosin, and visualized with a Zeiss
Axioplan microscope. For testicular analysis, seminiferous tubule
diameters were measured and interstitial cell numbers were
counted under randomly selected 206 power fields, blind to
genotype. Macroorchidism was assessed by combined weight of
both testes of Fmr1
I304N mice compared to that of either wt or Fmr1
null littermates at indicated ages. Measurements from multiple
litters of similar ages were pooled and subjected to statistical
analysis (student’s t-test). Both histology and testicular size
measurements were performed using mice bred greater than 10
generations into the C57BL/6 background (B6.Fmr1 null breeding
pairs were generously provided by Dr. W. Greenough, U. Illinois)).
Behavioral analysis
B6.Fmr1
I304N/+ heterozygous female mice were shipped to
Baylor College of Medicine where they were embryo rederived by
mating with male C57BL/6J mice. Female offspring were
backcrossed an additional generation to C57BL/6J male mice.
Mice used for behavioral analysis were generated by mating these
mice with B6.Fmr1
I304N/+ heterozygous females and were
maintained at the same B6 backcross generation. All mice started
testing between 2–3 months of age by experimenters blind to the
genotype of the mice using behavioral protocols previously
described [53,68]. Twenty-three mutant and 18 wild-type
littermates were evaluated for this study.
Behavioral results were analyzed using SPSS. Data were
analyzed using one- and two-way ANOVA with repeated
measures as appropriate. Significant interactions were analyzed
using simple-effects follow-up comparisons. Levels of significance
were set at p#0.05.
Electrophysiology
Hippocampal slices (400mm) were prepared from 30–90 day old
B6.Fmr1
I304N mice and their wt or B6.Fmr1 null littermates as
described [11,61]. All experiments were performed blind to
genotype and in the presence of the NMDA receptor antagonist
D,L-AP5 (50 mM; Tocris) to isolate mGluR-dependent LTD. D,L-
AP5 and anisomycin were prepared fresh daily in artificial
cerebrospinal fluid which consists of (in mM) NaCl, 124; KCl, 5;
NaH2PO4, 1.25; NaHCO3, 26; MgCl2, 1; CaCl2, 2; dextrose, 10.
Extracellular field potentials (FPs) were measured in the stratum
radiatum of hippocampal CA1 elicited by Schaffer collateral
stimulation. mGluR-LTD was induced by application of 100mM
DHPG for 5min or by pairs of stimuli (50 msec interstimulus
interval) delivered at 1 Hz for 20 min (2400 pulses; PP-LFS).
Synaptic strength was measured as the initial slope (10–40% of
the rising phase) of the FP. LTD magnitude was compared at
60–70min after the onset of DHPG or PP-LFS. Slices were
preincubated in antagonists or inhibitors for 20–30 min before
DHPG or PP-LFS. The effects of all pharmacological treatments
on LTD were evaluated by comparing interleaved control and
treated slices. Independent t-tests were used to determine statistical
significance.
Total protein extract for western blot
Fmr1
I304N mice and their wild type littermates on the FVB
background were used for determining FMRP levels by western
blot. Tissues were Dounce homogenized in lysis buffer (0.5% NP-
40, 0.5% deoxycholic acid, 0.1% SDS in PBS, 50% glycerol, and
16Complete protease inhibitor cocktail (Roche)) sonicated to fully
disrupt nuclei, shear nucleic acids and disrupt macromolecular
complexes, and spun at 20,0006ga t4 uC for 15min. Protein
concentration was determined by Bradford assay compared with
BSA standards. 50ug of protein from each sample was boiled in
SDS-sample buffer and used for western analysis.
Antibodies
The following antibodies were used throughout the work: anti-
FMRP mab2160 at 1:1000 for immunoblot (IB) (Chemicon), anti-
FMRP 2F5 at 1:100 for IB [84], anti-FMRP ab17722 at 1:1000
for immunoblot (Abcam), anti-FMRP 7G1-1 ascites (Develop-
mental Studies Hybridoma Bank (DSHB), University of Iowa) at
1:100 for IB, also used for IP as described [85,86], anti-FXR1P
ML13 at 1:10,000 for IB (gift from Dr. E. Khandjian (Universite ´
Laval, Quebec)), anti-FXR2P 1G2 concentrated supernatant at
1:100 for IB (DSHB), anti-hsp90 at 1:5000 for IB (BD Biosciences),
anti-gamma tubulin (GTU-88, Sigma) at 1:10,000 for IB, anti-
ribosomal S6 protein at 1:1000 for IB (Cell Signaling), human
patient serum against Nova at 1:1000 for IB [87], HRP-
conjugated anti-His-tag at 1:5000 for IB (Novagen). HRP-
conjugated anti-mouse, anti-rabbit, or anti-human IgG at
1:10,000 for IB (Jackson Immunoresearch).
Western blot
Samples were run on 8% or 4–12% gradient SDS-polyacryl-
amide gels and transferred to Immobilon-P membranes (Millipore)
by standard methods. Membranes were blocked for 1hr at room
temperature in 10% non-fat dry milk in western blot wash buffer
(WBWB) (23mM Tris, pH 8.0, 190mM NaCl, 0.1% w/v BSA,
1mM EDTA, 0.5% Triton X-100, 0.02% SDS). Primary
antibodies in 10% milk in WBWB were used during incubation
for 1 hr at room temperature or overnight at 4uC. Blots were
washed with WBWB 5 times for 5 min after each antibody
incubation. Signals were detected by enhanced chemilumines-
cence (Western Lightning detection kit, Perkin Elmer) and
quantified with a Versadoc Imaging System (Bio-Rad).
Quantitative RT–PCR
Purified RNA was reverse transcribed using random hexamers
(Roche) and Superscript III reverse transcriptase (Invitrogen)
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amplified using SYBR green PCR master mix (Applied Biosys-
tems) with 200nM of the following primers.
Fmr1 1F (spanning exon 2 to 3) 59-TGAAAACAACTGG-
CAACCAGAGAG-39
Fmr1 1R (spanning exon 2 to 3) 59-CAGGTGGTGG-
GAATCTCACATC-39
Fmr1 2F (spanning exon 10 to 11) 59-GTCAGGAGTTGT-
GAGGGTGAGG-39
Fmr1 2R (spanning exon 10 to 11) 59-GGAAGGTAGG-
GAACTTGGTGGC-39
Gapdh F5 9-CATGGCCTTCCGTGTTCCTA-39
Gapdh R5 9-GCGGCACGTCAGATCCA-39
Luc F5 9-GCCTTGATTGACAAGGATGGA-39
Luc R5 9-CAGAGACTTCAGGCGGTCAAC-39
Quantitative PCR amplification was performed using a
7900HT sequence detection system (Applied Biosystems) at the
Genomic Resource Center at The Rockefeller University.
Fluorimetric intensity of SYBR green was monitored during each
cycle of amplification to quantify mRNA levels. Regression curves
were drawn for each sample and relative amount of mRNA was
calculated from the threshold cycles using the instrument’s
software, SDS 2.0. For expression levels in total brain, relative
levels of Fmr1 mRNA were measured using the standard curve
method and normalized to the internal control GAPDH mRNA.
Three pairs of littermates were used for Fmr1 mRNA determina-
tion by Q-PCR. Error was calculated using the formula suggested
by the ABI user bulletin, [(std dev for Fmr1)
2 + (std dev for
Gapdh)
2]
0.5 For polyribosome distribution, relative Fmr1 or Gapdh
mRNA level in each fraction was normalized to spiked-in
luciferase RNA analyzed using the DDCt method. The amount
of Fmr1 mRNA in each fraction was then plotted as a percentage
of total Fmr1 mRNA summed over the entire polyribosome
gradient. Q-PCR experiments were each repeated 2 times with
two pairs of biologic replicates. Error bars reflect the technical
replicates from triplicate wells in a single representative experi-
ment from polysome gradients. Error is calculated using the
formula suggested by the ABI user bulletin, [(std dev for Fmr1)
2 +
(std dev for luc)
2]
0.5. Because of gradient variability from
day to day they cannot be plotted together so a representative
experiment is shown.
Mouse brain polyribosome analysis
Mouse brain polyribosomes were prepared essentially accord-
ing to established protocols [27,51]. Briefly, 2 week-old mice
were sacrificed by isoflurane anaesthesia and decapitation. The
brain was removed and placed in ice-cold dissection buffer
(10mM HEPES-KOH, pH 7.4, 150mM KCl, 5mM MgCl2,
100ug/ml cycloheximide). Cortex and cerebellum were dissected
free of underlying white matter, homogenized in 1ml lysis buffer
(10mM HEPES-KOH, pH 7.4, 150mM KCl, 5mM MgCl2,
0.5mM dithiothreitol, 100ug/ml cycloheximide, 16 Complete
EDTA-free protease inhibitor cocktail (Roche), 40U/ml rRNA-
sin (Promega)) per brain with 12 strokes at 900rpm in a motor-
driven Teflon-glass homogenizer. The homogenate was spun at
20006gf o r1 0 m i na t4 uC. The supernatant (S1) from the
homogenized material was collected and adjusted to 1% NP-40,
incubated for 5min on ice, and spun at 20,0006gf o r1 0 m i na t
4uC. The resulting supernatant (S2) was loaded onto a 20–50%
w/w linear density gradient of sucrose in 10mM HEPES-
KOH pH 7.4, 150mM KCl, and 5mM MgCl2. Gradients were
centrifuged at 40,000 rpm for 2 hrs at 4uCi naB e c k m a nS W 4 1
rotor. Fractions of 0.75ml volumew e r ec o l l e c t e dwith continuous
monitoring at 260nm using an ISCO UA-6 UV detector. 400 ul
of each fraction was TCA precipitated and analyzed by Western
blot.
Superose 6 gel filtration
A pre-packed Superose 6 Precision column PC 3.2/30 in a
SMART system (GE Healthcare) was used to determine the
molecular masses of protein complexes. The optimal separation
range of globular proteins in this column is 5 kDa to 5000 kDa
with an exclusion limit of 40,000 kDa. Mouse brain cytoplasmic
lysates (0.3% NP-40, 10mM HEPES, pH 7.4, 150mM KCl, either
with or without 30mM EDTA) were spun over a 0.22um Spin-X
column (Corning) before loading onto a Superose 6 column with a
flow rate of 30ul/min. Protein profile was monitored at A280nm
and fractions of 75ul were collected. Fractions were TCA
precipitated for Western analysis. To calibrate the column, protein
markers (GE Healthcare) were run and gave the following results:
blue dextran (void $40,000 kDa) in fraction 4, 669 kDa at the
fraction 10/11 boundary, 440 kDa in fraction 13, 67 kDa in
fraction 15/16 and 13.7 kDa in fraction 18. Molecular mass was
extrapolated by linear regression analysis for each fraction
according to the migration of these protein markers and used for
identification of protein complex sizes we studied. The average
MW in each fraction was: fraction 12 (463 kDa), 13 (261 kDa), 14
(148 kDa), 15 (83 kDa) and 16 (47 kDa). For complete RNase
digestion, recombinant RNase A and T1 (Ambion) were added to
mouse brain lysates to a final concentration of 20 ug/ml and
10,000 U/ml respectively. Lysates were incubated at room
temperature for 30 min before gel filtration.
Co-immunoprecipitation of FMRP and FXR1/2P
A 1:1 slurry of protein A Sepharose beads (Sigma) was first
bound to 120 ug of rabbit anti-mouse Fcc bridging antibody
(Jackson ImmunoResearch) for 20 minutes at room temperature,
washed 3 times in 0.1 M phosphate buffer pH 8.1, and bound to
10 ul of anti-FMRP monoclonal 7G1-1 ascites (5mg/ml, DSHB,
U. Iowa). Brain cytoplasmic lysates were prepared in lysis buffer
(0.5% Triton X-100, 30mM HEPES, pH 7.4, 200mM NaCl,
30mM EDTA, and Complete protease inhibitor cocktail (Roche)),
by Dounce homogenization of one adult brain in 2 ml lysis buffer
and centrifugation at 20,0006g for 10 minutes at 4 degrees, and
were incubated with beads and antibodies at 4uC for 2 hrs.
Immunoprecipitates were washed four times with the same lysis
buffer. Sepharose beads were heated to 95u in SDS sample loading
buffer and supernatants analyzed by Western analysis.
T7 transcription and directed UV crosslinking IP
96nt long G-quartet (GQ) and kissing complex (kc) RNAs
[51,64] were in vitro transcribed with P
32-a-UTP and P
32-a-GTP.
RNAs were gel purified on denaturing gels and spiked into 100ul
S2 brain lysate prepared as for polyribosome analysis from 2
month old mice of the indicated genotype. RNAs were incubated
with the brain lysates for 15 min at room temperature and then
UV crosslinked as described [88]. Lysates were then diluted with
500 ul stringent IP buffer (0.5% NP-40, 0.5% deoxycholic acid,
0.1% SDS in PBS) and the IP was performed as for the co-
immunoprecipitation, with the exception that stringent IP buffer
was both the IP and wash buffer. Immunoprecipitates were run on
4–12% SDS-PAGE, transferred to nitrocellulose membranes, and
exposed by autoradiography.
Supporting Information
Figure S1 Light micrographs of sagittal sections of Fmr1
I304N
knock-in mouse brains and testes reveal no microscopic abnor-
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paraffin embedded, sectioned, and stained with hematoxylin &
eosin. (A,B) Wild-type cerebellum, (C,D) I304N cerebellum, (E,F)
wild-type cortex, (G,H) I304N cortex, (I,J) wild-type hippocampus,
(K,L) I304N hippocampus, (M,N) wild-type testes, and (O,P)
I304N testes and photographed at two magnifications. FVB.
Fmr1
I304N mice have normal seminiferous tubular diameter (wild
type tubular diameter=177.5621.4 mm, n=30 and I304N
tubular diameter=176.0617.3 mm, n=30, p.0.05), normal
interstitial mass without edema (wild-type interstitial cell num-
ber=3368, n=10, I304N interstitial cell number=3265, n=10,
under 206field, p.0.05), and normal spermatogenesis.
Found at: doi:10.1371/journal.pgen.1000758.s001 (0.85 MB PDF)
Figure S2 Behavorial assays in Fmr1
I304N mice and their wild
type littermates. The findings for both day 1 and day 2 were
similar; day 1 data are presented, and details for each assay are
given below. Assays performed were as follows. Activity in open
field test: (A) total distance traveled, (B) vertical distance (rearing).
Anxiety related responses: (C) center:total distance ratio in an open
field, (D) light to dark transition, (E) time spent in the dark
chamber. Startle habituation: (F) acoustic startle response in PPI
test, (G) %PPI with increasing prepulse level. Conditioned fear:
(H) number of freezing bouts in the context test, (I) number of
freezing bouts in the acoustic conditioned stimulus test. (J)
Hotplate test for sensitivity to pain as measured by latency of
response. (K) Number of marbles buried as a measure of obsessive-
compulsive behavior. (L) % of mice displaying audiogenic seizure
in response to a stimulus.
Found at: doi:10.1371/journal.pgen.1000758.s002 (0.07 MB PDF)
Text S1 Locomotor activity in an open field, anxiety related
responses, acoustic startle and prepulse inhibition of the startle,
conditioned fear, hotplate, marble bury, audiogenic seizure.
Found at: doi:10.1371/journal.pgen.1000758.s003 (0.04 MB
DOC)
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